The present invention relates to ##STR00001##
or a pharmaceutically acceptable salt or ester prodrug thereof for use in the treatment of a mycobacterial infection or disease resulting from a mycobacterial infection, such as tuberculosis.

The present invention provides for methods, compositions, and kits pertaining to the treatment of various diseases associated with inflammation. In various aspects, the invention provides methods and compositions comprising an effective amount of a macrolide and an effective amount of a tetracycline.

The present invention provides for methods, compositions, and kits pertaining to the treatment of various diseases associated with inflammation. In various aspects, the invention provides methods and compositions comprising an effective amount of a macrolide and an effective amount of a tetracycline.

The present invention provides for methods, compositions, and kits pertaining to the treatment of various diseases associated with inflammation. In various aspects, the invention provides methods and compositions comprising an effective amount of a macrolide and an effective amount of a tetracycline.

Pharmaceutical compositions and methods for treating or preventing bacterial infections are disclosed. The pharmaceutical compositions typically comprise pharmaceutically effective amount of: (a) sulbactam or a pharmaceutically acceptable salt thereof, and (b) at least one beta-lactamase inhibitor or a pharmaceutically acceptable salt thereof, with the provision that the beta-lactamase inhibitor is not sulbactam.

Pharmaceutical compositions and methods for treating or preventing bacterial infections are disclosed. The pharmaceutical compositions typically comprise pharmaceutically effective amount of: (a) sulbactam or a pharmaceutically acceptable salt thereof, and (b) at least one beta-lactamase inhibitor or a pharmaceutically acceptable salt thereof, with the provision that the beta-lactamase inhibitor is not sulbactam.

Pharmaceutical compositions and methods for treating or preventing bacterial infections are disclosed. The pharmaceutical compositions typically comprise pharmaceutically effective amount of: (a) sulbactam or a pharmaceutically acceptable salt thereof, and (b) at least one beta-lactamase inhibitor or a pharmaceutically acceptable salt thereof, with the provision that the beta-lactamase inhibitor is not sulbactam.

The present invention relates to indoline alkaloid compounds. In particular, indoline alkaloid compounds of the invention have antibacterial activity and/or are capable of resensitizing the susceptibility of methicillin-resistant S. aureus to a β-lactam antibiotic. The present invention also relates to a method for producing and using the same.

The present invention relates to indoline alkaloid compounds. In particular, indoline alkaloid compounds of the invention have antibacterial activity and/or are capable of resensitizing the susceptibility of methicillin-resistant S. aureus to a β-lactam antibiotic. The present invention also relates to a method for producing and using the same.

The present invention relates to indoline alkaloid compounds. In particular, indoline alkaloid compounds of the invention have antibacterial activity and/or are capable of resensitizing the susceptibility of methicillin-resistant S. aureus to a β-lactam antibiotic. The present invention also relates to a method for producing and using the same.